Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides

Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,273 · see citing works

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · see citing works

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. ¹

Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · see citing works

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595 · see citing works

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594 · see citing works

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner‐Weir, S., Habener, J. F., & Egan, J. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · see citing works

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26

Marguet, D., Baggio, L. L., Kobayashi, T., Bernard, A., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538 · see citing works

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · see citing works

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

The structure and function of CD26 in the T‐cell immune response

Morimoto, C., & Schlossman, S. F. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01571.x · Cited by 423 · see citing works

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · see citing works

Critical Role of cAMP-GEFII·Rim2 Complex in Incretin-potentiated Insulin Secretion

Kashima, Y., Miki, T., Shibasaki, T., Ozaki, N., Miyazaki, M., Yano, H., & Seino, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108378200 · Cited by 383 · see citing works

CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes

Gorrell, M. D., Gysbers, V., & McCaughan, G. W. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00984.x · Cited by 363 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1× · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

Fehmann, H. C., & Habener, J. F. (1992) · Endocrinology · doi:10.1210/endo.130.1.1309325 · Cited by 337 · see citing works

Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

Creutzfeldt, W., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 328 · see citing works

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

Deacon, C. F., Hughes, T. E., & Holst, J. J. (1998) · Diabetes · doi:10.2337/diabetes.47.5.764 · Cited by 321 · see citing works

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.

Zhou, J., Wang, X., Piñeyro, M. A., & Egan, J. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319 · see citing works

Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 318 · see citing works

Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat

Larsen, P. J., Tang‐Christensen, M., & Jessop, D. S. (1997) · Endocrinology · doi:10.1210/endo.138.10.5270 · Cited by 316 · see citing works

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects

Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 308 · see citing works

Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1-(7–36) Amide or Exendin-(9–39) Alters Body Weight in the Rat**This work was supported by the United Kingdom Medical Research Council.

Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · see citing works

Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects

Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., & Habener, J. F. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.270 · Cited by 289 · see citing works

Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family

Lambeir, A., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Damme, J. V., & Meester, I. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103106200 · Cited by 271 · see citing works

Molecular characterization of dipeptidyl peptidase activity in serum

Durinx, C., Lambeir, A., Bosmans, E., Falmagne, J., Berghmans, R., Haemers, A., Scharpé, S., & Meester, I. D. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01634.x · Cited by 267 · see citing works

Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H. S., & Demuth, H. (1998) · Diabetes · doi:10.2337/diab.47.8.1253 · Cited by 267 · see citing works

GIF biology and fat metabolism

Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · see citing works

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

Rachman, J., Barrow, B. A., Lévy, J., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 265 · see citing works

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · see citing works

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J. D., Pørksen, N. K., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264 · see citing works

Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats

Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang‐Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 258 · see citing works

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

Knudsen, L. B., & Pridal, L. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00795-9 · Cited by 248 · see citing works

The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes

Egan, J. M., Clocquet, A. R., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8337 · Cited by 247 · see citing works

Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats

Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R. W., Parkhouse, W. S., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232 · see citing works

Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes

Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230 · see citing works

Impaired Incretin Response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men

Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J. R., Holst, J. J., & Åhrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 229 · see citing works

Gastric Inhibitory Polypeptide: the neglected incretin revisited

Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 228 · see citing works

Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1–Positive Pancreatic Ductal Cells Into Insulin-Secreting Cells

Hui, H., Wright, C. V. E., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 224 · see citing works

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 211 · see citing works

Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats

Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208 · see citing works

A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells

Wesley, U., Albino, A., Tiwari, S., & Houghton, A. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.190.3.311 · Cited by 207 · see citing works

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

Reimer, M. K., Holst, J. J., & Åhrén, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 196 · see citing works

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice

Åhrén, B., Holst, J. J., Mårtensson, H., & Balkan, B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00600-2 · Cited by 193 · see citing works

Glucagon-like peptide-1 is a physiological incretin in rat.

Wang, Z., Wang, R. M., Owji, A. A., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117671 · Cited by 190 · see citing works

Glucagon-Like Peptide-1 Inhibits Pancreatic ATP-Sensitive Potassium Channels via a Protein Kinase A- and ADP-Dependent Mechanism

Light, P. E., Fox, J. E. M., Riedel, M. J., & Wheeler, M. B. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0084 · Cited by 188 · see citing works

Activation of a cAMP-regulated Ca2+-Signaling Pathway in Pancreatic β-Cells by the Insulinotropic Hormone Glucagon-like Peptide-1

Holz, G. G., Leech, C. A., & Habener, J. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.17749 · Cited by 188 · see citing works

Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

Kolligs, F. T., Fehmann, H.-C., Göke, R., & Göke, B. (1995) · Diabetes · doi:10.2337/diab.44.1.16 · Cited by 185 · see citing works

Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene

Abbott, C. A., McCaughan, G. W., Baker, E., & Sutherland, G. R. (1994) · Immunogenetics · doi:10.1007/bf01246674 · Cited by 177 · see citing works

CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO

Ishii, T., Ohnuma, K., Murakami, A., Takasawa, N., Kobayashi, S., Dang, N. H., Schlossman, S. F., & Morimoto, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211439098 · Cited by 172 · see citing works

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose‐Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172 · see citing works

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

Larsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171 · see citing works

Regulation of Fibroblast Migration on Collagenous Matrix by a Cell Surface Peptidase Complex

Ghersi, G., Dong, H., Goldstein, L. A., Yeh, Y., Häkkinen, L., Larjava, H., & Chen, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202770200 · Cited by 167 · see citing works

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Pederson, R. A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F. C., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · see citing works

Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats

Sudre, B., Broqua, P., White, R. B., Ashworth, D. M., Evans, D. M., Haigh, R. M., Junien, J., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165 · see citing works

Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

Dupre, J., Behme, M. T., HRAMIAK, I. M., McFarlane, P. A., Williamson, M. P., Zabel, P. L., & McDonald, T. J. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 152 · see citing works

Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)*

Edvell, A., & Lindström, P. (1999) · Endocrinology · doi:10.1210/endo.140.2.6514 · Cited by 151 · see citing works

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146 · see citing works

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Deacon, C. F., Danielsen, P. L., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145 · see citing works

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

Gutniak, M., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139 · see citing works

Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat

Pospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 138 · see citing works

Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo

Steinbrecher, A., Reinhold, D., Quigley, L., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.2041 · Cited by 136 · see citing works

Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.

Beak, S. A., Heath, M. M., Small, C. J., Morgan, D. G., Ghatei, M. A., Taylor, A. D., Buckingham, J. C., Bloom, S. R., & Smith, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci610 · Cited by 133 · see citing works

Dipeptidyl Peptidase IV from Human Serum: Purification, Characterization, and N-Terminal Amino Acid Sequence

Iwaki-Egawa, S., Watanabe, Y., Kikuya, Y., et al. (1998) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022130 · Cited by 130 · see citing works

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats

Donahey, J. C. K., van Dijk, G., Woods, S. C., & Seeley, R. J. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01057-3 · Cited by 121 · see citing works

Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation

Ikushima, H., Munakata, Y., Ishii, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8439 · Cited by 119 · see citing works

Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM

Rachman, J., Gribble, F. M., Barrow, B. A., Lévy, J., Buchanan, K. D., & Turner, R. C. (1996) · Diabetes · doi:10.2337/diab.45.11.1524 · Cited by 119 · see citing works

Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes

Drucker, D. J. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397401 · Cited by 113 · see citing works

Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema

Lefebvre, J., Murphey, L. J., Hartert, T. V., Jiao Shan, R., Simmons, W. H., & Brown, N. J. (2002) · Hypertension · doi:10.1161/hy0202.103054 · Cited by 113 · see citing works

Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion

Lambeir, A., Durinx, C., Proost, P., Damme, J. V., Scharpé, S., & Meester, I. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02982-9 · Cited by 112 · see citing works

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

Pauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 103 · see citing works

Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats

Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Yoshikawa, S., Asano, O., & Tanaka, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4999 · Cited by 96 · see citing works

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95 · see citing works

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

Ling, Z., Wu, D., Zambre, Y., Flamez, D., Drucker, D. J., PIPELEERS, D. G., & Schuit, F. C. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000374 · Cited by 91 · see citing works

Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells

Wang, Y., Egan, J., Raygada, M. J., Nadiv, O., Roth, J., & Montrose‐Rafizadeh, C. (1995) · Endocrinology · doi:10.1210/endo.136.11.7588224 · Cited by 88 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist1

Lewis, J. T., Dayanandan, B., Habener, J. F., & Kieffer, T. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7750 · Cited by 85 · see citing works

Natural Substrates of Dipeptidyl Peptidase IV

Meester, I. D., Durinx, C., Bal, G., Proost, P., Struyf, S., Goossens, F. J., Augustyns, K., & Scharpé, S. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46826-3_7 · Cited by 84 · see citing works

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

Cordero, O. J., Ayude, D., Nogueira, M., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1410 · Cited by 84 · see citing works

Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levels

Hong, W., Petell, J. K., Swank, D. M., et al. (1989) · Experimental Cell Research · doi:10.1016/0014-4827(89)90296-6 · Cited by 84 · see citing works

Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells

Pethiyagoda, C. L., Welch, D. R., & Fleming, T. P. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1010930918055 · Cited by 82 · see citing works

Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice

Baggio, L. L., Kieffer, T. J., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7720 · Cited by 79 · see citing works

Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase

Hegen, M., Kameoka, J., Dong, R., Schlossman, S. F., & Morimoto, C. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00053.x · Cited by 78 · see citing works

Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis

Cordero, O. J., Salgado, F. J., Mera, A., et al. (2001) · Rheumatology International · doi:10.1007/s002960100134 · Cited by 76 · see citing works

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

Jones, I. R., Owens, D. R., Moody, A. J., Luzio, S. D., Morris, T., & Hayes, T. M. (1987) · Diabetologia · doi:10.1007/bf00296993 · Cited by 75 · see citing works

Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells

Beak, S. A., Small, C. J., Иловайская, И. А., Hurley, J. D., Ghatei, M. A., Bloom, S. R., & Smith, D. M. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828468 · Cited by 71 · see citing works

Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

Ikushima, H., Munakata, Y., Iwata, S., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00010-2 · Cited by 70 · see citing works

Metabolism of glucagon by dipeptidyl peptidase IV (CD26)

Pospisilik, J. A., Hinke, S. A., Pederson, R. A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U. F., McIntosh, C. H. S., & Demuth, H. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00170-1 · Cited by 70 · see citing works

Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

Gutniak, M., Juntti‐Berggren, L., Hellström, P. M., Guenifi, A., Holst, J. J., & Efendić, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.857 · Cited by 70 · see citing works

Renal Catabolism of Truncated Glucagon-Like Peptide 1

Ruiz-Grande, C., Alarcón, C., Alcántara, A., Castilla, C., Novoa, J. L., Villanueva‐Peñacarrillo, M. L., & Valverde, I. (1993) · Hormone and Metabolic Research · doi:10.1055/s-2007-1002190 · Cited by 68 · see citing works

CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma

Tanaka, T., Umeki, K., Yamamoto, I., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640508 · Cited by 65 · see citing works

Dipeptidyl peptidase IV and adenosine deaminase activity

Elgün, S., Keskinege, A., & Kumbasar, H. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00039-6 · Cited by 62 · see citing works

Involvement of Dipeptidyl Peptidase IV in Extravillous Trophoblast Invasion and Differentiation

Sato, Y., Fujiwara, H., Higuchi, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020038 · Cited by 62 · see citing works

Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.

Scrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B. A., & Drucker, D. J. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1552 · Cited by 61 · see citing works

Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa

Grouzmann, E., Monod, M., Landis, B. N., Wilk, S., Brakch, N., Nicoucar, K., Giger, R., Malis, D. D., Szalay‐Quinodoz, I., Cavadas, C., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0939fje · Cited by 59 · see citing works

Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective

Deacon, C. F., & Holst, J. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00359-5 · Cited by 56 · see citing works

A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence

Hildebrandt, M., Reutter, W. G., Arck, P., et al. (2000) · Clinical Science · doi:10.1042/cs19990368 · Cited by 55 · see citing works

Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers

Maes, M. H. J., Meester, I. D., Verkerk, R. M., Medts, P. D., Wauters, A., Vanhoof, G., Vandoolaeghe, E., Neels, H. M., & Scharpé, S. (1997) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(96)00040-6 · Cited by 54 · see citing works

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes

Todd, J. F., Edwards, C. M. B., Ghatei, M. A., Mather, H. M., & Bloom, S. R. (1998) · Clinical Science · doi:10.1042/cs0950325 · Cited by 53 · see citing works

An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy

Keane, N. M., Price, P., Lee, S., et al. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01647.x · Cited by 51 · see citing works

Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: Experimental and clinical evidence

Perner, F., Gyuris, T., Rákóczy, G., et al. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90054-9 · Cited by 40 · see citing works

Good or evil: CD26 and HIV infection

Ohtsuki, T., Tsuda, H., & Morimoto, C. (2000) · Journal of Dermatological Science · doi:10.1016/s0923-1811(99)00081-x · Cited by 39 · see citing works

Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells.

Poulsen, M., Hansen, G. H., Dabelsteen, E., et al. (1993) · Journal of Histochemistry & Cytochemistry · doi:10.1177/41.1.8093256 · Cited by 38 · see citing works

Serum Dipeptidyl Peptidase IV (DPP IV, CD26) Activity in Chronic Hepatitis C

Firneisz, G., Lakatos, P. L., & Szalay, F. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750313423 · Cited by 34 · see citing works

G1/S cell cycle arrest provoked in human T cells by antibody to CD26

Ohnuma, K., Ishii, T., Iwata, S., Hosono, O., Kawasaki, H., Uchiyama, M., Tanaka, H., Yamochi, T., Dang, N. H., & Morimoto, C. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01510.x · Cited by 30 · see citing works

Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients.

Gotoh, H., Hagihara, M., Nagatsu, T., et al. (1988) · Clinical Chemistry · doi:10.1093/clinchem/34.12.2499 · Cited by 28 · see citing works

Differential Expression of Dipeptidyl Peptidase IV (CD26) and Thyroid Peroxidase in Neoplastic Thyroid Tissues.

Umeki, K., Tanaka, T., Yamamoto, I., et al. (1996) · Endocrine Journal · doi:10.1507/endocrj.43.53 · Cited by 26 · see citing works

Structure of CD26 (Dipeptidyl Peptidase IV) and Function in Human T Cell Activation

Hegen, M., Kameoka, J., Dong, R.-P., et al. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9613-1_15 · Cited by 21 · see citing works

T-Cell Immune Parameters and Depression in Patients With Crohn's Disease

Rose, M., Hildebrandt, M., Fliege, H., Seibold, S., Mönnikes, H., & Klapp, B. F. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200201000-00008 · Cited by 21 · see citing works

Dipeptidyl Peptidase IV (CD26): Role in T Cell Activation and Autoimmune Disease

Reinhold, D., Hemmer, B., Gran, B., et al. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_17 · Cited by 17 · see citing works

Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs

Kawai, K., Suzuki, S., Ohashi, S., Mukai, H., Murayma, Y., & Yamashita, K. (1990) · European Journal of Endocrinology · doi:10.1530/acta.0.1230661 · Cited by 17 · see citing works

Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies

Sakamoto, J., Watanabe, T., Teramukai, S., et al. (1993) · Journal of Surgical Oncology · doi:10.1002/jso.2930520214 · Cited by 16 · see citing works

Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients

Uematsu, T., Urade, M., Yarnaoka, M., et al. (1996) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1996.tb00306.x · Cited by 16 · see citing works

Dipeptidyl Peptidase IV (DPP IV, CD26) In Patients With Mental Eating Disorders

Hildebrandt, M., Rose, M., Mayr, C., et al. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_22 · Cited by 15 · see citing works

Involvement of Dipeptidyl Peptidase IV in Immune Complex–Mediated Glomerulonephritis

Shinosaki, T., Kobayashi, T., Kimura, K., et al. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780443 · Cited by 10 · see citing works

Rebuttal to Deacon and Holst: “Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1” versus “Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”

Demuth, H., Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00753-2 · Cited by 10 · see citing works

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

Butterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402 · see citing works

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383 · see citing works

The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369 · see citing works

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · see citing works

Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis

Drucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274 · see citing works

In beta-cells, mitochondria integrate and generate metabolic signals controlling insulin secretion

Maechler, P., Carobbio, S., & Rubi, B. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.006 · Cited by 140 · see citing works

Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP

Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94 · see citing works

Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats

Giannocco, G., Oliveira, K. C., Crajoinas, R. O., Venturini, G., Salles, T. A., Fonseca-Alaniz, M. H., Maciel, R. M. B., & Girardi, A. C. C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.043 · Cited by 68 · see citing works

Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study

Alkabbani, W., Suissa, K., Gu, K. D., Cromer, S. J., Paik, J. M., Bykov, K., Hobai, I., Thompson, C. C., Wexler, D. J., & Patorno, E. (2024) · BMJ · doi:10.1136/bmj-2024-080340 · Cited by 60 · see citing works

A model of GLP-1 action on insulin secretion in nondiabetic subjects

Dalla Man, C., Micheletto, F., Sathananthan, A., Rizza, R. A., Vella, A., & Cobelli, C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00705.2009 · Cited by 45 · see citing works

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

Reimer, M. K., Holst, J. J., & Åhrén, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 196 · see citing works

D‐420720, A novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition

Tsai, H. J., Chou, S., Chuang, S., Chen, C., & Hsu, F. (2008) · Drug Development Research · doi:10.1002/ddr.20278 · Cited by 9 · see citing works

Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin

Taldone, T., Zito, S. W., & Talele, T. T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.107 · Cited by 13 · see citing works

Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?

Juillerat‐Jeanneret, L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400658e · Cited by 204 · see citing works

Dipeptidyl Peptidase IV Inhibition Improves Impaired Glucose Tolerance in High-Fat Diet-Fed Rats: Study Using a Fischer 344 Rat Substrain Deficient in Its Enzyme Activity

Mitani, H., Takimoto, M., Hughes, T. E., & Kimura, M. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.88.442 · Cited by 63 · see citing works